Certara announced Thursday it has named a new CEO.
The Princeton-based drug development solutions company said Dr. William F. Feehery has been named CEO and member of the board of directors, effective June 3.
Feehery previously was at DuPont Industrial Biosciences where he served as president since 2013. He joined DuPont in 2002 and before that had experience in venture capital and was a consultant for the Boston Consulting Group.
“I am excited to join Certara, an exceptional company that is reducing the cost, time, and risk of drug development. I could not have made a better choice than to join the company at this exciting time in its growth trajectory,” Feehery said. “Certara’s track record for optimizing drug development and patient care decision-making by leveraging its integrated portfolio of quantitative and in silico capabilities is impeccable. The company has already had a significant positive impact, helping to bring safer and more effective new therapies to market efficiently. The healthcare field is ripe for accelerated innovation of this type and Certara is poised to lead the market.”
Certara also announced Dr. Edmundo Muniz, who’s been Certara’s CEO since June 2014, will become a member of the board of directors and chair of the board’s newly-created science committee.
“We are very pleased to welcome Bill to Certara. Bill’s broad and diverse background in technology and commercial operations position him well to lead the company. We are confident that his technical, operational and commercial expertise will serve him well as he takes the company to its next level of growth,” Sheri McCoy, Certara chairman of the board, said. She went on to say that “we also want to thank Edmundo for the great work he has done in establishing the vision and strategy that has resulted in Certara becoming the world leader in model-informed drug development and a critical innovator in modeling and simulation.”
